Amlodipine And Olmesartan Medoxomil
Product Images NDC 45865-935

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Olmesartan Medoxomil (NDC 45865-935). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp1 (923)

A label for Amlodipine and Olmesartan Medoxomil tablets, strength 5/20 mg, generic for Azo. It includes prescription information from Glenmark Pharmaceuticals Ltd., indicating a quantity of 30 tablets and notes specific warnings and dosing instructions. The label features lot number, expiration date placeholders, and peel-off instructions on the side.*

FDA Label Image

Pdp2 (935)

Amlodipine and Olmesartan Medoxomil tablets 5 mg/40 mg blister pack label. The label indicates the product is generic for Azor and manufactured by Glenmark Pharma Ltd, India. It contains dosing instructions, a warning about dizziness and pregnancy, lot number, expiration date, and a quantity of 30 tablets in the pack.*

FDA Label Image

Amlodipine.jpg (Amlodipine)

Chemical structure diagram showing two molecular components associated with Amlodipine and Olmesartan Medoxomil. The left structure depicts a complex organic molecule with multiple rings, chlorine, methoxy groups, and amine functional groups. The right structure features a benzene ring bonded to a sulfonic acid group, indicating the medoxomil moiety.*

FDA Label Image

Figure1.jpg (Figure1)

A line graph showing the relationship between baseline systolic blood pressure (SBP) in mmHg on the x-axis and the percentage of subjects with SBP less than 140 mmHg on the y-axis. Four groups are plotted: Placebo, Amlodipine 10 mg, Olmesartan Medoxomil 40 mg, and Amlodipine and Olmesartan Medoxomil tablets 10/40 mg, demonstrating comparative effects on SBP reduction.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph showing the relationship between baseline diastolic blood pressure (DBP) in mmHg and the percentage of subjects with DBP less than 90 mmHg, comparing placebo, Olmesartan Medoxomil 40 mg, Amlodipine 10 mg, and Amlodipine and Olmesartan Medoxomil tablets 10/40 mg.*

FDA Label Image

Figure3.jpg (Figure3)

A line graph showing the percentage of subjects with systolic blood pressure less than 130 mmHg versus baseline systolic blood pressure in mmHg. The graph compares effects of Placebo, AML 10 mg, OM 40 mg, and Amlodipine and olmesartan medoxomil tablets 10/40 mg groups over a baseline range of 140 to 180 mmHg.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph comparing the percentage of diastolic blood pressure (DBP) readings below 80 mmHg versus baseline DBP (mmHg) for four groups: Placebo, AML 10 mg, OM 40 mg, and Amlodipine and Olmesartan Medoxomil tablets 10/40 mg. The graph shows decreasing trends of % DBP <80 mmHg as baseline DBP increases from 95 to 110 mmHg, with the combination tablets having the highest percentage values.*

FDA Label Image

Olmesartanmedoxomil.jpg (Olmesartanmedoxomil)

Chemical structure of Amlodipine, part of the combined active ingredients Amlodipine and Olmesartan Medoxomil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.